Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2067871 | 0.88 | ALOX5 (0.46) | ALOX5ALDH1A1KDM4EGAAGLA | |
| SCHEMBL2067727 | 0.77 | GAA (0.38) | ALDH1A1KDM4EGAAGLA | |
| SCHEMBL27090280 | 0.77 | KDM4E (0.53) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL21994456 | 0.74 | MEN1 (0.34) | ALDH1A1HPGD | |
| SCHEMBL2068758 | 0.73 | CHIA (0.38) | ALDH1A1KDM4EGAAHPGD | |
| SCHEMBL2069207 | 0.68 | SMN1; SMN2 (0.50) | ALDH1A1GAAHPGD | |
| SCHEMBL2067879 | 0.67 | ALOX5 (0.40) | ALOX5ALDH1A1KDM4EHPGDMAOA | |
| SCHEMBL18207261 | 0.65 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGD | |
| SCHEMBL6281925 | 0.64 | CES1 (0.34) | ALDH1A1KDM4E | |
| SCHEMBL27863520 | 0.64 | KDM4E (0.56) | ALDH1A1KDM4EGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | ALOX5 3509/4885ALDH1A1 2405/4885KDM4E 1280/4885 |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | ALOX5 3509/4885ALDH1A1 2405/4885KDM4E 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.